PMID- 23429762 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20130225 LR - 20211021 IS - 1738-1088 (Print) IS - 2093-4327 (Electronic) IS - 1738-1088 (Linking) VI - 10 IP - 1 DP - 2012 Apr TI - No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients. PG - 49-53 LID - 10.9758/cpn.2012.10.1.49 [doi] AB - OBJECTIVE: This study examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in treatment-refractory depression. METHODS: The study enrolled 64 patients meeting the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder who were treated with at least two courses of a single antidepressant, but who had Hamilton Depression Rating Scale (HAMD-17) scores >/=15 points that were reduced less than 50% over at least a 4-week treatment period. There were 24 males and 40 females (age range 27-68 years; mean+/-SD, 48+/-13 years). The patients' clinical improvement was evaluated using the HAMD-17. Patients with at least a 50% decrease in the HAMD-17 score were defined as responders. Serum BDNF levels were assayed using enzyme-linked immunosorbent assays and the presence of the BDNF (Val66Met) polymorphism was determined using the TaqMan genotyping assay. RESULTS: No correlation was found between the BDNF (Val66Met) polymorphism and a positive response to adding an atypical antipsychotic drug. No differences were observed in the changes in the serum BDNF levels and HAMD-17 scores between Val66Val and Met-carriers. In addition, in patients who experienced remission, the atypical antipsychotic drug was discontinued after at least 3 months of treatment and the patients were then followed for 1 year; 14 of 27 patients (52%) relapsed within 1 year. CONCLUSION: These results suggest that the BDNF (Val66Met) polymorphism is not associated with the response to the augmentation of a SSRI or SNRI with an atypical antipsychotic drug, and that the combination of an atypical antipsychotic drug and a SSRI or SNRI should be continued for 3 months or more in refractory depressed patients in the Japanese population. FAU - Yoshimura, Reiji AU - Yoshimura R AD - Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Kishi, Taro AU - Kishi T FAU - Hori, Hikaru AU - Hori H FAU - Ikenouchi-Sugita, Atsuko AU - Ikenouchi-Sugita A FAU - Umene-Nakano, Wakako AU - Umene-Nakano W FAU - Katsuki, Asuka AU - Katsuki A FAU - Hayashi, Kenji AU - Hayashi K FAU - Iwata, Nakao AU - Iwata N FAU - Nakamura, Jun AU - Nakamura J LA - eng PT - Journal Article DEP - 20120430 PL - Korea (South) TA - Clin Psychopharmacol Neurosci JT - Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology JID - 101207332 PMC - PMC3569156 OTO - NOTNLM OT - Antipsychotic drug OT - Brain-derived neurotrophic factor OT - Polymorphism OT - Selective Serotonin Reuptake Inhibitor OT - Serotonin Norepinephrine Reuptake Inhibitor OT - Treatment-resistant depressive disorder EDAT- 2013/02/23 06:00 MHDA- 2013/02/23 06:01 PMCR- 2012/04/01 CRDT- 2013/02/23 06:00 PHST- 2011/10/20 00:00 [received] PHST- 2012/01/07 00:00 [revised] PHST- 2012/02/20 00:00 [accepted] PHST- 2013/02/23 06:00 [entrez] PHST- 2013/02/23 06:00 [pubmed] PHST- 2013/02/23 06:01 [medline] PHST- 2012/04/01 00:00 [pmc-release] AID - 10.9758/cpn.2012.10.1.49 [doi] PST - ppublish SO - Clin Psychopharmacol Neurosci. 2012 Apr;10(1):49-53. doi: 10.9758/cpn.2012.10.1.49. Epub 2012 Apr 30.